Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAcute LeukemiasAggressive LymphomasT-Cell and NK-Cell NeoplasmsDiseaseAcute Lymphoblastic LeukaemiaNHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-PositiveNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, Mediastinal (Thymic) Large B-Cell LymphomaNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK-positiveNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK negativeNHL, T-Cell Type, AngioimmunoblasticNHL, T-Cell Type, Enteropathy TypeNHL, T-Cell Type, HepatosplenicNHL, T-Cell Type, Lymphoblastic LymphomaNHL, T-Cell Type, Other Specified Leukemias, Aggressive NK-Cell LeukemiaNHL, T-Cell Type, Peripheral, UnspecifiedSubgroupB-ALLICD10C82.-C82.7C82.9C83.3C83.5C83.7C84.4C84.6C84.7C85.2C86.1C86.2C86.5C91.0-C94.7-MeSHLymphoma, Large-Cell, AnaplasticLymphoma, Large B-Cell, DiffusePrecursor B-Cell Lymphoblastic Leukemia-LymphomaSequenceGMALL 08/2013-B-ALL/NHL 2002 Regimen, 18 - 55GMALL 08/2013-B-ALL/NHL 2002 regimen, older than 55, B-ALL onlyGMALL 08/2013-B-ALL/NHL 2002 regimen, older than 55, NHL onlySTUDY - levelChemotherapyChemo-substanceGemcitabineNivolumabOxaliplatinRituximabChemo-substanceGemcitabineNivolumabOxaliplatinRituximabChemo-substanceGemcitabineNivolumabOxaliplatinRituximabChemo-substanceGemcitabineNivolumabOxaliplatinRituximabNo. Substances123 RadiotherapySupportive therapySupportive substanceAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDimetindenGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDimetindenGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDimetindenGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDimetindenGranisetronParacetamolPegfilgrastimPrednisoloneNo. Substances147Protocol classificationTherapy classificationcurrent standardStudy protocol, currentIntensityStandard doseTherapy indicationFirst lineSecond lineTherapy phaseConsolidationTherapy intentioncurativepalliativeRisksEmetogenicity (MASCC/ESMO) only studiesPublicationAuthorHeld GHoelzer DDiseaseHochmaligne B-ALL und B-NHL bei Erwachsenen, Erstlinierezidivierendes (erstlinie mit Anthrazyklin) oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2, ECOG 0-2rezidivierendes oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2OriginGerman Multicenter Study Group for Adult Acute Lymphoblastic LeukemiaInternal Medicine I Saarland University Medical School, DSHNHL 2015-1Protocols in Revision 5 protocols foundProtocols under revision.GMALL 08/2013 - B-ALL/NHL 2002 regimen, Rituximab consolidation (PID784 V1.0)Study - Level - Gemcitabine 1000 / Oxaliplatin 100, Aggressive Non-Hodgkin Lymphoma (PID972 V1.0)Study - Level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, Cycle 1 (PID968 V1.2)Study - level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, cycle 2+ (PID970 V1.2)Study - Level - Nivolumab 240, diffuse large B-Non-Hodgkin Lymphoma, consolidation (PID971 V1.1)
